Overview

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study (*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients. (*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Clinico Humanitas
Treatments:
Niacinamide
Sorafenib